logo-loader

Tissue Regenix on hunt for new chief executive as Odell steps down

Published: 08:10 18 Oct 2017 BST

picture of surgery
Cartilage replacements are one of Tissue's products

Regenerative med-tech Tissue Regenix Group PLC (LON:TRX) is on the hunt for a new chief executive after Antony Odell stepped down.

Odell had been in the role since 2008 and will be replaced temporarily by non-executive chairman, John Samuel, who will step into an executive role until a new CEO is found.

READ: Tissue Regenix sees revenues double in ‘transformational’ first half

Tissue Regenix has pioneered a cell washing technology that allows grafts and replacement implants without rejection and most recently acquired Texas-based rival Cellright, which uses a similar technique for bone grafts.  

Samuel said the integration of CellRight continues as planned and current trading remains in line with management expectations.

READ: Tissue Regenix confirms US$30mln acquisition of bone graft specialist Cellright

He thanked Odell for his dedication and commitment since he was appointed.

“During his tenure the company has listed on the AIM market, successfully commercialised products in the US and earlier this year completed the transformational acquisition of CellRight. “

Tissue Regenix Group says "disciplined approach" paying off at half-year stage

Tissue Regenix Group PLC (AIM:TRX) chief executive Danny Lee and chief financial officer David Cocke speak to Thomas Warner from Proactive London after the regenerative medicine company released its interim results for the first six months of 2023. Cocke reports that the company reported a...

on 5/9/23